AIDS patients face Roche’s resistance over Fuzeon price

Published: 2008-07-08 07:00:00

Updated: 2008-07-08 07:00:00

The price of Fuzeon, a new drug for AIDS, will be unlikely determined sooner or later since Roche, the maker of the drug, is calling for a more “profitable'' price, while patients are asking for something that is affordable.

The Ministry of Health, Welfare and Family Affairs suggested 25,000 w...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK